SCHEMBL27010071

SCHEMBL27010071

COc1cccc2c1CCN2C(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.55
DRD2 P14416 4/20 0.45
DRD3 P35462 3/20 0.45
DRD1 P21728 1/20 0.45
DRD5 P21918 1/20 0.45
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
DRD4 P21917 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
AADAT Q8N5Z0 1/20 0.39
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
ADRB1 P08588 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTR3A P46098 1/20 0.39
HTR6 P50406 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
SIGMAR1 Q99720 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24317347 0.90 NOTUM (0.49) NOTUMDRD2DRD3DRD1DRD5
SCHEMBL2625801 0.77 NOTUM (0.59) NOTUMDRD2DRD3DRD1DRD5
SCHEMBL17173258 0.77 NOTUM (0.51) NOTUMDRD2HTR2CHTR2BDRD4
SCHEMBL6999610 0.76 NOTUM (0.45) NOTUMDRD2DRD3DRD1DRD5
SCHEMBL2632953 0.76 NOTUM (0.53) NOTUMDRD2DRD3HTR2CDRD4
SCHEMBL13180753 0.76 DRD2 (0.42) NOTUMDRD2DRD3DRD1DRD5
SCHEMBL27010069 0.76 NOTUM (0.53) NOTUMDRD2DRD3DRD4KDM4E
SCHEMBL26650896 0.76 ADRA2C (0.37) NOTUMKDM4E
SCHEMBL9914264 0.76 FAAH (0.36) NOTUMHTR2CHTR2BALDH1A1
SCHEMBL12905309 0.75 NOTUM (0.56) NOTUMDRD2DRD3DRD1DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 NOTUM 1676/4885DRD2 4598/4885DRD3 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.